发现和演变的柏柏林类似物作为抗Helicobacter pylori的药物,具有多目标机制
Xin Zhang1, Genzhu Wang2, Wenhua Kuang3
1Department of Clinical Pharmacy, Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, Shandong, 272000, China.
Bioorganic chemistry
|July 17, 2024
概括
新的柏柏林 (BBR) 衍生物显示出强大的抗Helicobacter pylori (HP) 活性,即使对抗耐药菌株. 这些化合物表现出良好的安全性和多目标机制,使它们成为进一步研究的有希望的候选者.
科学领域:
- 药用化学 医学化学
- 微生物学 微生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 杆菌 (HP) 感染是全球主要的健康问题,通常与抗生素耐药性有关.
- 耐美醇 (MTZ) 的HP菌株需要开发新的治疗药物.
研究的目的:
- 为了合成和评估新型的抗HP活性的protoberberine衍生物.
- 为了确定具有有利的药理动力学特性的强效和安全的抗HP药物.
主要方法:
- 合成了30种原贝贝林衍生物,其中25种是新型化合物.
- 使用最小抑制度 (MIC) 试验对抗美特里纳醇耐药和敏感菌株的抗HP活性进行体外评估.
- 评估类似药物的特征,包括毒性,血稳定性和人造胃液稳定性.
- 涉及HP尿酶抑制和细菌膜透性试验的机制研究.
主要成果:
- 柏柏林 (BBR) 衍生物7c对六种耐MTZ和两种易MTZ的HP菌株表现出最高功效,MIC值在0.4-1.6μg/mL之间.
- 化合物7c表现出有利的类似药物的特性,包括低毒性和高稳定性在血和人造胃液中.
- 机械研究表明,7c向HP尿酶 (IC50 = 0.27μg/mL对抗杰克豆尿酶),改变细菌膜的透性,并与HPDNA相互作用.
结论:
- BBR衍生品代表了一个有前途的新类抗HP剂.
- 化合物7c由于其强大的杀菌活性,多目标机制和有利的安全概况,具有显著的潜力.
- 这些发现需要进一步调查BBR衍生物作为新型抗HP疗法.
相关概念视频
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
345
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
345
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
415
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
415
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
365
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
365
Peptic Ulcer Disease IV: Management
83
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
83
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
364
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
364
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
390
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
390


